SI1040838T1 - Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione - Google Patents

Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

Info

Publication number
SI1040838T1
SI1040838T1 SI200030109T SI200030109T SI1040838T1 SI 1040838 T1 SI1040838 T1 SI 1040838T1 SI 200030109 T SI200030109 T SI 200030109T SI 200030109 T SI200030109 T SI 200030109T SI 1040838 T1 SI1040838 T1 SI 1040838T1
Authority
SI
Slovenia
Prior art keywords
isoindol
dione
piperidine
dihydro
oxo
Prior art date
Application number
SI200030109T
Other languages
English (en)
Slovenian (sl)
Inventor
Tieno Dr. Germann
Heinrich Kugelmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19914621A external-priority patent/DE19914621C2/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of SI1040838T1 publication Critical patent/SI1040838T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200030109T 1999-03-31 2000-03-01 Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione SI1040838T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19914621A DE19914621C2 (de) 1997-10-06 1999-03-31 Stabile wässrige Lösung von EM 12
EP00104208A EP1040838B1 (de) 1999-03-31 2000-03-01 Stabile wässrige Lösung von 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion

Publications (1)

Publication Number Publication Date
SI1040838T1 true SI1040838T1 (en) 2003-08-31

Family

ID=7903088

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030109T SI1040838T1 (en) 1999-03-31 2000-03-01 Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

Country Status (26)

Country Link
US (1) US6306879B1 (pt)
EP (1) EP1040838B1 (pt)
JP (1) JP2000290180A (pt)
KR (1) KR20010006930A (pt)
CN (1) CN1270027A (pt)
AR (1) AR023199A1 (pt)
AT (1) ATE235256T1 (pt)
AU (1) AU766250B2 (pt)
BR (1) BR0001112A (pt)
CA (1) CA2302886A1 (pt)
CO (1) CO4970704A1 (pt)
DE (1) DE50001522D1 (pt)
DK (1) DK1040838T3 (pt)
ES (1) ES2194640T3 (pt)
HK (1) HK1033645A1 (pt)
HU (1) HUP0001312A2 (pt)
IL (1) IL135340A0 (pt)
NO (1) NO20001658L (pt)
NZ (1) NZ503428A (pt)
PE (1) PE20001597A1 (pt)
PL (1) PL339336A1 (pt)
PT (1) PT1040838E (pt)
RU (1) RU2238727C2 (pt)
SI (1) SI1040838T1 (pt)
SK (1) SK4632000A3 (pt)
ZA (1) ZA200001618B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268148B2 (en) * 1999-05-20 2007-09-11 Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
DE19957342A1 (de) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Verfahren zur Behandlung und/oder Prophylaxe von IL-12-bedingten Erkrankungen
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2002098376A1 (en) * 2001-06-06 2002-12-12 The Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
JP4494013B2 (ja) * 2001-08-06 2010-06-30 ザ チルドレンズ メディカル センター コーポレイション 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性
CA2808646C (en) 2003-09-17 2016-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098505T3 (es) 1991-04-17 1997-05-01 Gruenenthal Chemie Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen

Also Published As

Publication number Publication date
PE20001597A1 (es) 2001-01-20
CO4970704A1 (es) 2000-11-07
ATE235256T1 (de) 2003-04-15
SK4632000A3 (en) 2000-10-09
HK1033645A1 (en) 2001-09-14
NO20001658D0 (no) 2000-03-30
PT1040838E (pt) 2003-08-29
AU2420400A (en) 2000-10-05
ZA200001618B (en) 2000-10-25
US6306879B1 (en) 2001-10-23
AR023199A1 (es) 2002-09-04
ES2194640T3 (es) 2003-12-01
DE50001522D1 (de) 2003-04-30
KR20010006930A (ko) 2001-01-26
AU766250B2 (en) 2003-10-09
IL135340A0 (en) 2001-05-20
NO20001658L (no) 2000-10-02
DK1040838T3 (da) 2003-05-26
PL339336A1 (en) 2000-10-09
EP1040838A1 (de) 2000-10-04
JP2000290180A (ja) 2000-10-17
CN1270027A (zh) 2000-10-18
HUP0001312A2 (en) 2001-03-28
RU2238727C2 (ru) 2004-10-27
BR0001112A (pt) 2001-08-21
CA2302886A1 (en) 2000-09-30
NZ503428A (en) 2001-08-31
HU0001312D0 (en) 2000-06-28
EP1040838B1 (de) 2003-03-26

Similar Documents

Publication Publication Date Title
DK1129088T3 (da) Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben
ZA200108867B (en) Piperidine derivatives useful as CCR5 antagonists.
ZA200108868B (en) Piperazine derivatives useful as CCR5 antagonists.
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
HK1046909A1 (en) Piperazine derivatives as 5-ht1b antagonists.
MXPA02008402A (es) Derivados de quinolina como antagonistas alfa-2.
HK1061563A1 (en) Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv
ZA200110254B (en) Process for the preparation of herbicidal derivatives.
HK1033645A1 (en) Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
NO20024197L (no) Fremgangsmåte ved fremstilling av 5-cyano-1-(4-fluorfenyl)- 1,3-dihydroisobenzofuraner
HU0001034D0 (en) Aqueous stable lysine solution
PL351884A1 (en) Novel indole derivatives
HUP0301038A3 (en) Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine
ZA200108392B (en) Process for the preparation of substituted pyrimidines.
IL150336A0 (en) Novel indole derivatives
FR2815332B1 (fr) Devidoir suspendu, notamment pour cultures
IL150010A0 (en) Heterocyclic derivatives
DK1456197T3 (da) Piperidin-2,6-dioner, som er substitueret heterocyklisk i 3-stillingen
EP1202738A4 (en) DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS
HK1046907A1 (zh) 製備咪唑烷-2-酮衍生物的方法
SI1147083T1 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
TW383003U (en) Improved structure of the strolling machine
TW393943U (en) Structural improvement of drawer
GB9929038D0 (en) Heterocyclic derivatives
SI1421075T1 (sl) Derivati piperidina, koristni kot antagonisti CCR5